The primary purpose of this study is to assess if the Test product (ADX-629), is safe and effective to treat mild asthma brought on by allergens in comparison to a Placebo.
2-year medical history of mild asthma
Allergy to house dust mites (HDM) or cats
No recent hospitalization with asthma in the last 6 months
Has not received allergen immunotherapy treatment with cat or HDM within the previous 5 years
Ability to tolerate temporary withdrawal of current asthma medication
Non-smokers within the past 1 year having not used tobacco products (i.e. cigarettes, cigars, pipe tobacco) or electronic cigarettes or other inhaled nicotine delivery products
Other inclusion/exclusion criteria will be assessed
This study has been approved by Advarra Ethics Board
75 days total, 13 sessions
Initial phone screening will be conducted by the recruitment team and then followed by a clinic phone assessment to determine eligibility prior to medical screening. The study consists of 13 in-clinic visits, two at home treatment periods and two 2-week washout periods at designated time points. COVID-19 testing will be conducted prior to designated visits.
Up to $4060
4520 Dixie Rd Mississauga, Ontario, Canada, L4W 1N2